Novocure Executive and Leadership Team

Francis Leonard, the Chief Executive Officer at Novocure, directs the company's overarching strategy and global operations. Leonard guides Novocure's mission to extend survival for patients with aggressive cancers, focusing on the commercialization and development of Tumor Treating Fields therapy. This leadership role involves steering clinical trial investigations across multiple cancer types, including brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. Leonard ensures alignment with regulatory bodies and market demands across Novocure's international presence, spanning Switzerland, the U.S., Germany, Japan, and Israel. The Chief Executive Officer's oversight extends to fostering innovation and driving the expansion of Tumor Treating Fields into new therapeutic areas, directly impacting the company's market position and financial performance. Francis Leonard's strategic vision is central to advancing Novocure's goal of transforming cancer treatment paradigms.

Mukund Paravasthu, the Chief Operating Officer at Novocure, oversees the company's global operational infrastructure and execution. Paravasthu manages the day-to-day business activities critical to Novocure's commercialization of Tumor Treating Fields therapy, ensuring efficient production and delivery across its target markets. This executive directs the scaling of operations to support ongoing clinical trials and the expansion of approved indications in countries like the U.S. and certain European nations. The Chief Operating Officer's responsibilities include optimizing supply chain logistics and ensuring compliance with international manufacturing standards. Mukund Paravasthu's focus is on enhancing operational efficiency and supporting the strategic growth initiatives that extend patient survival in aggressive cancers. This leadership ensures the seamless integration of Novocure's innovative therapy into healthcare systems worldwide.

Matthew Thaeder, the Chief of Staff To President at Novocure, provides critical strategic support and operational coordination. Thaeder facilitates the execution of key initiatives and ensures seamless communication across executive functions, directly supporting the President's strategic objectives. This role involves managing cross-functional projects and driving operational improvements that align with Novocure's mission to extend survival in aggressive cancers. The Chief of Staff To President works closely with various departments to streamline processes and enhance the company's ability to commercialize its Tumor Treating Fields therapy. Matthew Thaeder's contributions are vital in optimizing the company's strategic direction and operational effectiveness, ensuring alignment with Novocure's global expansion efforts in oncology. This position is integral to maintaining momentum in research and commercial development.

Uri Weinberg, the Chief Innovation Officer & Chief Medical Officer at Novocure, spearheads the company's research and development pipeline and medical strategy. Weinberg directs the scientific exploration and clinical validation of Tumor Treating Fields therapy across a spectrum of aggressive cancers, including ongoing trials in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. This dual role ensures that medical insights inform innovation, driving the development of next-generation oncology treatments. Uri Weinberg oversees the clinical trial design and execution, ensuring adherence to the highest medical and ethical standards across Novocure's global operations. The Chief Innovation Officer & Chief Medical Officer's leadership is fundamental to advancing Novocure's commitment to extending patient survival and establishing Tumor Treating Fields as a standard of care in oncology.